Long-term safety of duloxetine during open-label compassionate use treatment of patients who completed previous duloxetine clinical trials

References

• Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002;63:308-15
   PubMed Web of Science ®Google Scholar
• Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res 2002;36:383-90
   PubMed Web of Science ®Google Scholar
• Perahia DG, Maina G, Thase ME, et al. Duloxetine in the prevention of depressive recurrences: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2009;70:706-16
   PubMed Web of Science ®Google Scholar
• Kornstein SG, Russell JM, Spann ME, et al. Duloxetine in the treatment of generalized anxiety disorder. Expert Rev Neurother 2009;9:155-65
   PubMed Web of Science ®Google Scholar
• Raskin J, Pritchett YL, Wang F, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 2005;6:346-56
   PubMed Web of Science ®Google Scholar
• Wernicke JF, Pritchett YL, D'souza DN, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 2006;67:1411-20
   PubMed Web of Science ®Google Scholar
• Arnold LM, Lu Y, Crofford LJ, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004;50:2974-84
   PubMed Web of Science ®Google Scholar
• Arnold LM, Rosen A, Pritchett YL, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005;119:5-15
   PubMed Web of Science ®Google Scholar
• Russell IJ, Mease PJ, Smith TR, et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 2008;136:432-44
   PubMed Web of Science ®Google Scholar
• Chappell AS, Ossanna MJ, Liu-Seifert H, et al. Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-Week, randomized, placebo-controlled trial. Pain 2009;146:253-60
   PubMed Web of Science ®Google Scholar
• Skljarevski V, Desaiah D, Liu-Seifert H, et al. Efficacy and safety of duloxetine in patients with chronic low back pain. Spine 2010;35:E578-85
   Google Scholar
• Skljarevski V, Ossanna M, Liu-Seifert H, et al. A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain. Eur J Neurol. 2009;16:1041-48
   PubMed Web of Science ®Google Scholar
• Nemeroff CB, Schatzberg AF, Goldstein DJ, et al. Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull 2002;36:106-32
   PubMedGoogle Scholar
• Acharya N, Rosen AS, Polzer JP, et al. Duloxetine: meta-analyses of suicidal behaviors and ideation in clinical trials for major depressive disorder. J Clin Psychopharmacol 2006;26:587-94
   PubMed Web of Science ®Google Scholar
• Hudson JI, Wohlreich MM, Kajdasz DK, et al. Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials. Hum Psychopharmacol 2005;20:327-41
   PubMed Web of Science ®Google Scholar
• Gahimer J, Wernicke J, Yalcin I, et al. A retrospective pooled analysis of duloxetine safety in 23,983 subjects. Curr Med Res Opin 2007;23:175-84
   PubMed Web of Science ®Google Scholar
• Pederson AG. Citalopram and suicidality in adult major depression and anxiety disorders. Nord J Psychiatry 2006;60:392-99
   PubMed Web of Science ®Google Scholar
• Wagner W, Plekkenpol B, Gray TE, et al. Review of fluvoxamine safety database. Drugs 1992;43(Suppl. 2):48-53
   PubMedGoogle Scholar
• Lane PW. Handling drop-out in longitudinal clinical trials: a comparison of the LOCF and MMRM approaches. Pharm Stat 2008;7:93-06
   PubMed Web of Science ®Google Scholar
• Prakash A, Risser RC, Mallincrodt CH. The impact of analytic method on interpretation of outcomes in longitudinal clinical trials. Int J Clin Pract 2008;62:1147-58
   PubMed Web of Science ®Google Scholar
• Mallinckrodt CH, Clark WS, David SR. Accounting for dropout bias using mixed-effects models. J Biopharm Stat 2001;11:9-21
   PubMedGoogle Scholar
• Mallinckrodt CH, Clark WS, David SR. Type I error rates from mixed effects model repeated measures versus with fixed effects ANOVA with missing values imputed via last observation carried forward. Drug Inf J 2001;35:1215-25
   Web of Science ®Google Scholar
• Mallinckrodt CH, Kaiser CJ, Watkin JG, et al. Type I error rates from likelihood-based repeated measures analyses of incomplete longitudinal data. Pharm Stat 2004;3:171-86
   Web of Science ®Google Scholar
• Mallinckrodt CH, Kaiser CJ, Watkin JG, et al. The effect of correlation structure on treatment contrasts estimated from incomplete clinical trial data with likelihood-based repeated measures compared with last observation carried forward ANOVA. Clin Trials 2004;1:477-48
   PubMedGoogle Scholar
• Mallinckrodt CH, Lane PW, Schnell D, et al. Recommendations for the primary analysis of continuous endpoints in longitudinal clinical trials. Drug Inf J 2008;42:303-19
   Google Scholar
• Mallinckrodt CH, Watkin JG, Molenberghs G, et al. Choice of the primary analysis in longitudinal clinical trials. Pharm Stat 2004;3:161-69
   Web of Science ®Google Scholar
• Goldman LS, Alexander RC, Luchins DJ. Monoamine oxidase inhibitors and tricyclic antidepressants: comparison of their cardiovascular effects. J Clin Psychiatry 1986;47:225-29
   PubMed Web of Science ®Google Scholar
• Wong DT, Bymaster FP. Dual serotonin and noradrenaline uptake inhibitor class of antidepressants potential for greater efficacy or just hype? Prog Drug Res 2002;58:169-22
   PubMedGoogle Scholar
• Raskin J, Wang F, Pritchett YL, et al. Duloxetine for patients with diabetic peripheral neuropathic pain: a 6-month open-label safety study. Pain Med 2006;7:373-85
   PubMed Web of Science ®Google Scholar
• Skljarevski V, Desaiah D, Zhang Q, et al. Evaluating the maintenance of effect of duloxetine in patients with diabetic peripheral neuropathic pain. Diabetes Metab Res Rev 2009;25:623-31
   PubMed Web of Science ®Google Scholar